Vivanza Biosciences

BSE: 530057 19 Aug 2025

Healthcare

₹ 2.15

Vivanza Biosciences Limited specializes in Pharmaceuticals within the Healthcare sector.

Vivanza Biosciences

BSE: 530057 19 Aug 2025

Healthcare

₹ 2.15

Vivanza Biosciences Limited specializes in Pharmaceuticals within the Healthcare sector.

Book Value

1.0

Dividend Yield

0.0%

Debt to Equity

1.52

Stock P/E

Market Cap

9.48 Cr

Vivanza Biosciences - Share Price & Details

Market Cap

₹9.48

High /Low

6.09 / 1.9

Stock P/E

Book Value

₹1.0

Dividend Yield

0.0

ROCE

-3.76

ROE

₹-16.0

Face Value

1.0

PEG Ratio

EVEBITDA

₹-47.1

Debt

6.10

CMP / FCF

-49.0

Debt to equity

₹1.52

NP Ann

-0.70

High price all time

21.0

Piotroski score

₹1.0

Graham Number

No. Eq. Shares

4.0

Net CF

₹-0.04

Net profit

-0.70

Price to book value

2.36

Interest Coverage

₹-0.97

Low price all time

0.44

Industry PE

33.8

Reserves

₹0.02

Free Cash Flow

₹-2.48

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
Shyama Computronics and Servic	1.48	0.93	0.67	0.00	5.33	35.5
Triochem Products Ltd.,	3.25	-4.52	NA	-18.44	0
Vivanza Biosciences Limited	5.29	-9.98	4.83	-0.25	9.48
DHANVANTRI JEEVAN REKHA LTD.	59.40	0.30	58.30	0.45	8.65	21.1
Satiate Agri Limited	1.74	-10.35	1.00	-3.54	8.55

Peer Comparison Chart

About Vivanza Biosciences

Vivanza Biosciences Limited, with Security Code 530057, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Vivanza Biosciences Reports Mixed Financial Results Amid Sales Growth and Declining Profitability in August 2025

(14 Aug 2025)

Vivanza Biosciences has reported its financial results for the quarter ending June 2025, showcasing its highest quarterly net sales in five...

Vivanza Biosciences consolidated net profit declines 66.67% in the June 2025 quarter

(13 Aug 2025)

Net profit of Vivanza Biosciences declined 66.67% to Rs 0.09 crore in the quarter ended June 2025 as against Rs 0.27 crore during the previous quarter ended...

Vivanza Biosciences to conduct board meeting

(13 Aug 2025)

Vivanza Biosciences will hold a meeting of the Board of Directors of the Company on 13 August 2025. More News. Company Logo.

How volatile is ProShares Trust ProShares UltraPro MidCap400 stock compared to the market - Capitalize on market momentum for maximum gains

(07 Aug 2025)

【Stock Observations】✌️ Stop settling for 10% yearly returns — our stock picks are engineered to help you grow 2x faster or more.

Can Vivanza Biosciences Limited (530057) Maintain Its Valuation - Invest smarter with actionable trading signals

(04 Aug 2025)

Can Vivanza Biosciences Limited (530057) Maintain Its Valuation ✌️【Market Focus】✌️ Why settle for average returns when you can earn over...

What makes Viemed Healthcare Inc. stock price move sharply - Earnings Report Outlook For 2025

(04 Aug 2025)

【Investor Updates】✌️ Expert predictions on high-growth stocks, supported by real-time market data and trends to help you make the best...

Quarterly Table

Standalone Consolidated

Metrics	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	1.0	4.8	6.0	4.9	3.9	3.4	2.3	0.4	1.6	0.8
Expenses	1.0	4.3	6.0	4.5	3.6	3.1	2.4	0.1	1.5	0.6
Operating Profit	0.0	0.5	0.0	0.4	0.2	0.3	-0.1	0.3	0.1	0.1
OPM %	1.05%	10.81%	0.75%	8.7%	6.3%	7.96%	-5.87%	74.53%	6.25%	15.62%
Other Income	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0
Interest	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Profit before tax	0.1	0.4	0.1	0.3	0.2	0.2	-0.3	0.2	0.0	0.0
Tax %	0%	0%	-187.3%	0%	0%	0%	41.9%	0%	0%	0%
Net Profit	0.1	0.4	-0.1	0.3	0.2	0.2	-0.4	0.2	0.0	0.0
EPS in Rs	0.37	1.04	-0.14	0.01	0.05	0.01	-0.09	0.06		0.01

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	5.9	8.2	9.2	7.6	6.6	4.4	2.4	3.0	1.5	0.5
Expenses	5.3	8.2	8.6	7.3	6.3	4.6	2.1	2.9	1.4	1.4
Operating Profit	0.6	0.0	0.6	0.3	0.3	-0.1	0.4	0.1	0.1	-0.9
OPM %	9.56%	-0.04%	6.42%	4.19%	4.45%	-3.03%	14.68%	3.67%	8.33%	-193.37%
Other Income	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Interest	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Profit before tax	0.5	0.0	0.5	0.3	0.2	-0.3	0.3	0.0	0.0	-1.0
Tax %	0%	-786.7%	0%	0%	0%	55.6%	0%	0%	0%	0%
Net Profit	0.5	-0.1	0.5	0.3	0.2	-0.4	0.3	0.0	0.0	-1.0
EPS in Rs	1.15	-0.26	0.12	0.07	0.01	-0.1	0.07		0.01	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	0%
5 Years:	-21%
3 Years:	-31%
TTM:	-80%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	-319%

Stock Price CAGR
10 Years:	15%
5 Years:	0%
3 Years:	-47%
1 Year:	-61%

Compounded Sales Growth
10 Years:	0%
5 Years:	-5%
3 Years:	-11%
TTM:	-73%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	-222%

Stock Price CAGR
10 Years:	15%
5 Years:	0%
3 Years:	-47%
1 Year:	-61%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Vivanza Biosciences

Vivanza Biosciences

Vivanza Biosciences - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About Vivanza Biosciences

Latest News

Vivanza Biosciences Reports Mixed Financial Results Amid Sales Growth and Declining Profitability in August 2025

Vivanza Biosciences consolidated net profit declines 66.67% in the June 2025 quarter

Vivanza Biosciences to conduct board meeting

How volatile is ProShares Trust ProShares UltraPro MidCap400 stock compared to the market - Capitalize on market momentum for maximum gains

Can Vivanza Biosciences Limited (530057) Maintain Its Valuation - Invest smarter with actionable trading signals

What makes Viemed Healthcare Inc. stock price move sharply - Earnings Report Outlook For 2025

Vivanza Biosciences Limited (530057)’s Trend in 2025 - Achieve breakthrough performance in the market

Vivanza Biosciences Limited (530057) Announces Strategic Shift - Invest smarter with data-backed insights

Minerals Inc. stock price move sharply - Invest smarter with daily stock recommendations

AstraZeneca Pharma India Limited (506820) Expands into New Market - Game-changing returns

Rajshree Polypack Limited (RPPL) Hits 52 Week High - Free Investment Case Studies

What are the latest earnings results for Rigel Pharmaceuticals Inc. - Invest smarter with expert stock recommendations

Artelo Biosciences Inc. Stock Analysis and Forecast - Free Wealth Planning Blueprint

Does Noah Holdings Limited Depositary Receipt stock pay reliable dividends - Free Stock Market Real-Time Monitoring

Is Vivanza Biosciences Limited (530057) a Good Long Term Bet - Outstanding trading profits

Vivanza Biosciences Limited (530057) Announces Strategic Shift - Superior portfolio returns

What drives Flowco Holdings Inc. stock price - Superior return velocity

What drives Ring Energy Inc. stock price - Remarkably fast returns

Ken Financial Services Limited (530547) Gets Regulatory Approval - Explosive trading opportunities

Vivanza Biosciences Limited (530057) Sees Unusual Trading Volume - Explosive earnings growth

Vivanza Biosciences Limited (530057)’s Trend in 2025 - Free Investment Case Studies

Vivanza Biosciences Limited (530057)’s Trend in 2025 - Massive stock growth

What drives SB.PRD stock price - Rapid growth trajectories

Technical Analysis: Skipper Limited (SKIPPERPP) - Accelerated investment success

Technical Analysis: Sumitomo Chemical India Limited (542920) - Explosive earning power

India Best Stocks for Small Investors High Growth Investment Options - Superior returns

Vivanza Biosciences Limited (530057) Signs Major Deal - Skyrocketing investment returns

Vivanza Biosciences Limited (530057) Stock Experiences Sudden Dip - High-velocity gains

Vivanza Biosciences Limited (530057)’s Trend in 2025 - Massive wealth growth

Vivanza Biosciences Limited (530057)’s Trend in 2025 - Free Stock Selection

Vivanza Biosciences Limited (530057) Stock Experiences Sudden Dip - Free Capital Allocation Plans

Vivanza Biosciences Limited (530057) Signs Major Deal - Dynamic profit expansion

How to Capitalize on India’s Economic Growth Through Stocks Investment Portfolio Booster - Skyrocketing profit margins

Bullish Pattern Emerging on Vivanza Biosciences Limited (530057) - Exceptional market performance

Analyzing the Best Performing IPOs in Stock Market Intelligent Investment Decisions - High-margin investment plays

Is Vivanza Biosciences Limited (530057) a Good Long Term Bet - Exceptional trading performance

Vivanza Biosciences Limited (530057) Sees Unusual Trading Volume - Rapidly growing investment returns

Stocks with Rising Popularity in India AI Backed Financial Forecasting - Outstanding stock performance

Naksh Precious Metals Limited (539402) Expands into New Market - Overwhelming financial success

Technical Analysis: Vivanza Biosciences Limited (530057) - Consistent triple-digit returns

Technical Analysis: Vivanza Biosciences Limited (530057) - Consistent high-performance stocks

Wabash National Corporation Stock Analysis and Forecast - Outstanding trading profits

Best AI Stocks Expert Selected Market Trends - Triple-digit returns

Best Stocks for Inflation Hedge Premium Investor Club Insights - Outstanding trading profits

Top Performing Stocks on the NSE in India Premium Stock Insights - Explosive trading opportunities

Best Dividend Growth Stocks in India Premium Stock Trading Group - Explosive earning power

Is Vivanza Biosciences Limited (530057) a Good Long Term Bet - Unstoppable profit momentum

Vivanza Biosciences Limited (530057)’s Trend in 2025 - Free Predictions

Published on: 2025-07-19 09:21:13

Is Kelly Services Inc. a good long term investment - Outstanding trading profits

Vivanza Biosciences Faces Intense Selling Pressure Amid Significant Price Declines

Krishna Institute of Medical Sciences consolidated net profit rises 55.42% in the March 2025 quarter

Tata Steel consolidated net profit rises 112.73% in the March 2025 quarter

Prudent Corporate Advisory Services consolidated net profit rises 16.09% in the March 2025 quarter

Share Market Today | Latest Stock Market News, Sensex Today and Nifty Live Updates

Vivanza Biosciences Reports Significant Operational Challenges in March 2025 Financial Results

Vivanza Bio Standalone March 2025 Net Sales at Rs 0.17 crore, down 92.62% Y-o-Y

Vivanza Bio Consolidated March 2025 Net Sales at Rs 0.48 crore, down 89.08% Y-o-Y

Arco Leasing reports consolidated net loss of Rs 0.04 crore in the March 2025 quarter

Board Meeting Outcome for Outcome Of Board Meeting Held Today 12Th May 2025

VIVANZA BIOSCIENCES ANNOUNCES BOARD MEETING DATE

Sellwin Traders consolidated net profit rises 42.86% in the March 2025 quarter

Q4 Results Today: Tata Steel, Raymond, PVR Inox, Ather Energy Among 80 Firms To Declare Earnings On May 12

Q4 Results 2025 Today, May 12: Tata Steel, SRF, UPL, PVR Inox among 80 NSE, BSE companies to declare quarterly earnings

Q4 results: Tata Steel, Raymond, SRF, Ather Energy, PVR Inox, UPL, others to declare earnings on May 12; check list

Vivanza Biosciences to hold board meeting

Vivanza Biosciences Hits All-Time Low Amidst Ongoing Financial Challenges and Declining Stakeholder Confidence

Vivanza Biosciences Hits 52-Week Low Amid Ongoing Financial Challenges and Stakeholder Concerns

Vivanza Biosciences Faces Challenges Amid Significant Stock Decline and Weak Fundamentals

Vivanza Biosciences Faces Major Financial Challenges Amidst Declining Stakeholder Confidence

Vivanza Biosciences Hits All-Time Low Amid Ongoing Financial Struggles and Volatility